KCS Wealth Advisory trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,936 shares of the company’s stock after selling 102 shares during the quarter. KCS Wealth Advisory’s holdings in Johnson & Johnson were worth $282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Financial Advantage Inc. purchased a new position in shares of Johnson & Johnson in the 3rd quarter worth about $28,000. Kessler Investment Group LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $29,000. Eii Capital Management Inc. purchased a new position in shares of Johnson & Johnson in the 3rd quarter worth about $39,000. Permanens Capital L.P. boosted its holdings in shares of Johnson & Johnson by 33.3% in the 3rd quarter. Permanens Capital L.P. now owns 400 shares of the company’s stock worth $52,000 after buying an additional 100 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its holdings in shares of Johnson & Johnson by 1.0% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 416,526 shares of the company’s stock worth $58,000 after buying an additional 3,994 shares during the last quarter. 67.28% of the stock is currently owned by hedge funds and other institutional investors.
In other news, EVP Kathryn E. Wengel sold 2,017 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $141.07, for a total transaction of $284,538.19. Following the sale, the executive vice president now directly owns 51,736 shares in the company, valued at $7,298,397.52. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Hubert Joly purchased 5,000 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were bought at an average price of $141.28 per share, for a total transaction of $706,400.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at $706,400. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
JNJ has been the topic of a number of research analyst reports. Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Friday, October 11th. Raymond James cut their price target on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Wells Fargo & Co boosted their price objective on Johnson & Johnson from $155.00 to $165.00 and gave the company an “overweight” rating in a research note on Thursday, January 9th. Finally, Credit Suisse Group restated a “buy” rating and issued a $163.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, December 31st. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus target price of $159.33.
Shares of Johnson & Johnson stock opened at $147.01 on Thursday. Johnson & Johnson has a 52-week low of $125.00 and a 52-week high of $147.84. The stock’s 50-day simple moving average is $143.07 and its 200 day simple moving average is $134.77. The stock has a market capitalization of $385.62 billion, a P/E ratio of 17.97, a P/E/G ratio of 2.36 and a beta of 0.71. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The business had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. During the same period in the previous year, the business posted $2.05 EPS. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. Equities research analysts forecast that Johnson & Johnson will post 8.66 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th will be paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date is Monday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Liquidity
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.